GlassScriptPhysician profile
Anup Lal
NPI 1184735300
$8,043.26
in general payments reported to CMS, 2019-2025
58 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $689 · 2021: $575 · 2022: $308 · 2023: $688 · 2024: $1,953 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964 · Education: $76.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.39 |
| Education | $76.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $931.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $848.67 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $645.50 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Merck Sharp & Dohme LLC | $481.90 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $393.22 | 2019-2025 | |
| Genentech USA, INC. | $272.84 | 2019-2025 | Polivy, Columvi, Venclexta |
| Amgen INC. | $266.12 | 2019-2023 | Kyprolis, Blincyto |
| Lilly USA, LLC | $256.65 | 2019-2025 | Verzenio, Jaypirca |
| Genzyme Corporation | $242.20 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $234.59 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| E.R. Squibb & Sons, L.L.C. | $206.81 | 2019-2025 | Opdivo |
| Celgene Corporation | $197.63 | 2019-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $191.86 | 2019-2025 | Trodelvy |
| Abbvie INC. | $181.42 | 2019-2025 | |
| Astellas Pharma US INC | $180.29 | 2024-2025 | Padcev, Xtandi, Xospata |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $150.61 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $146.57 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Eisai INC. | $138.00 | 2019-2025 | |
| Sobi, INC | $135.96 | 2024-2025 | |
| Daiichi Sankyo INC. | $133.20 | 2023-2025 | Vanflyta, Enhertu |
| Rigel Pharmaceuticals, INC. | $127.40 | 2019-2021 | |
| Beigene USA, INC. | $123.96 | 2023-2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $121.36 | 2023-2025 | Fotivda |
| Seagen INC. | $98.40 | 2021-2023 | Padcev, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $87.00 | 2019-2025 | Iclusig, Fruzaqla |
| Kite Pharma, INC. | $85.24 | 2023-2025 | Yescarta |
| Amag Pharmaceuticals, INC. | $82.87 | 2019-2021 | |
| Puma Biotechnology, INC. | $79.73 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $79.18 | 2019-2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $76.01 | 2021-2025 | Libtayo |
| Tesaro, INC. | $64.51 | 2019 | |
| Beone Medicines USA, INC. | $62.41 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $62.26 | 2025 | |
| Array Biopharma INC | $57.93 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $55.04 | 2019-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $46.98 | 2024 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $39.17 | 2019-2022 | |
| Caris Mpi, INC. | $34.79 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $29.63 | 2019-2023 | Zoladex |
| Janssen Pharmaceuticals, INC | $29.57 | 2020 | |
| Amneal Pharmaceuticals LLC | $27.96 | 2025 | Alymsys |
| Jazz Pharmaceuticals INC. | $27.74 | 2025 | |
| Pharmacosmos Therapeutics INC. | $26.42 | 2025 | Monoferric |
| Myriad Genetic Laboratories, INC. | $24.92 | 2025 | Myrisk |
| Alexion Pharmaceuticals, INC. | $24.52 | 2019 | |
| Acrotech Biopharma INC. | $23.88 | 2024 | Beleodaq |
| Emd Serono, INC. | $23.43 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.04 | 2025 | Danziten |
| Immunogen, INC. | $20.51 | 2024 | Elahere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.30 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.16 | 2025 | Empaveli |
| Novocure INC. | $17.52 | 2025 | Optune Gio |
| Mirati Therapeutics, INC. | $16.00 | 2024 | Krazati |
| Inari Medical, INC. | $15.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Deciphera Pharmaceuticals INC. | $15.29 | 2022 | |
| Fortovia Therapeutics, INC. | $13.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anup Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.